Status:

COMPLETED

Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally

Lead Sponsor:

Instituto Nacional de Saúde, Mozambique

Collaborating Sponsors:

World Health Organization

Conditions:

Polio

Eligibility:

All Genders

2-2 years

Phase:

PHASE2

Brief Summary

Polio is an acute transmissible disease caused by any of the three polio virus serotypes (types 1, 2 or 3). In Mozambique, polio vaccination is part of the immunization schedule of the expanded vaccin...

Eligibility Criteria

Inclusion

  • Children whose parents/guardians consent to their participation;
  • Children whose parents/guardians live in the study area and do not intend to depart during the study period.

Exclusion

  • Children whose parents are under the legal age with exception of 16-years-old parents who are already living in marital status;
  • Children whose parents have mental illness;
  • Children with immunosuppression.

Key Trial Info

Start Date :

August 6 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 31 2022

Estimated Enrollment :

382 Patients enrolled

Trial Details

Trial ID

NCT04027036

Start Date

August 6 2020

End Date

May 31 2022

Last Update

January 31 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Instituto Nacional de Saúde-Mozambique CISPOC

Maputo, Mozambique, 21-462867

2

INSMozambique

Maputo, Mozambique

Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally | DecenTrialz